Thrombospondin-1 (TSP-1) is a matricellular glycoprotein that belongs to a family of evolutionary highly conserved calcium-binding proteins consisting of 5 members (TSP-1–TSP-5). In the eye, TSP-1 is expressed by several ocular cell types and is also detectable in the aqueous humor and the vitreous body. So far, TSP-1 is one of the major activators of TGFβ, suggesting a strong influence on various important cellular functions and interactions such as differentiation, migration, and wound healing. TSP-1 is also a key endogenous inhibitor of hem- and lymphangiogenesis. Several lines of evidence indicate a crucial role of TSP-1 in maintaining the ocular immune and angiogenic privilege, for example, by regulating T lymphocytes and the tolerance-promoting properties of ocular antigen-presenting cells. This review discusses the role of TSP-1 in dry eye disease and corneal graft rejection through its effects on hem- and lymphangiogenesis, as well as on the underlying immune responses. Recent work will be reviewed showing by which molecular mechanism TSP-1 modulates inflammatory processes during ocular diseases. This opens potential new treatment avenues in inflammatory and (lymph)angiogenic ocular diseases.
Get full access to this article
View all access options for this article.
References
1.
LawlerJ.W., SlayterH.S., and ColiganJ.E.Isolation and characterization of a high molecular weight glycoprotein from human blood platelets. J. Biol. Chem., 253:8609–8616, 1978.
2.
AdamsJ.C., and LawlerJ.The thrombospondins. Cold Spring Harbor Perspect. Biol., 3:a009712, 2011.
3.
TanK., and LawlerJ.The interaction of thrombospondins with extracellular matrix proteins. J. Cell Commun. Signal., 3:177–187, 2009.
4.
WightT.N., RaugiG.J., MumbyS.M., and BornsteinP.Light microscopic immunolocation of thrombospondin in human tissues. J. Histochem. Cytochem., 33:295–302, 1985.
5.
Flugel-KochC., OhlmannA., FuchshoferR., Welge-LussenU., and TammE.R.Thrombospondin-1 in the trabecular meshwork: localization in normal and glaucomatous eyes, and induction by TGF-beta1 and dexamethasone in vitro. Exp. Eye Res., 79:649–663, 2004.
6.
SekiyamaE., NakamuraT., CooperL.J., et al.Unique distribution of thrombospondin-1 in human ocular surface epithelium. Invest. Ophthalmol Vis. Sci., 47:1352–1358, 2006.
7.
HiscottP., SeitzB., Schlotzer-SchrehardtU., and NaumannG.O.Immunolocalisation of thrombospondin 1 in human, bovine and rabbit cornea. Cell Tissue Res., 289:307–310, 1997.
8.
Miyajima-UchidaH., HayashiH., BeppuR., et al.Production and accumulation of thrombospondin-1 in human retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci., 41:561–567, 2000.
9.
SheibaniN., SorensonC.M., CorneliusL.A., and FrazierW.A.Thrombospondin-1, a natural inhibitor of angiogenesis, is present in vitreous and aqueous humor and is modulated by hyperglycemia. Biochem. Biophys. Res. Commun., 267:257–261, 2000.
10.
BornsteinP.Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J. Cell Biol., 130:503–506, 1995.
11.
SchaumbergD.A., SullivanD.A., and DanaM.R.Epidemiology of dry eye syndrome. Adv. Exp. Med. Biol., 506:989–998, 2002.
12.
SternM.E., BeuermanR.W., FoxR.I., et al.The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea., 17:584–589, 1998.
13.
The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul. Surf., 5:75–92, 2007.
14.
SternM.E., and PflugfelderS.C.Inflammation in dry eye. Ocul. Surf., 2:124–130, 2004.
15.
KongL., RobinsonC.P., PeckA.B., et al.Inappropriate apoptosis of salivary and lacrimal gland epithelium of immunodeficient NOD-scid mice. Clin. Exp. Rheumatol., 16:675–681, 1998.
16.
MathersW.D., LaneJ.A., and ZimmermanM.B.Tear film changes associated with normal aging. Cornea., 15:229–234, 1996.
17.
PatelS., and FarrellJ.C.Age-related changes in precorneal tear film stability. Optom. Vis. Sci., 66:175–178, 1989.
18.
SullivanB.D., EvansJ.E., DanaM.R., and SullivanD.A.Influence of aging on the polar and neutral lipid profiles in human meibomian gland secretions. Arch. Ophthalmol., 124:1286–1292, 2006.
19.
SternM.E., GaoJ., SchwalbT.A., et al.Conjunctival T-cell subpopulations in Sjogren's and non-Sjogren's patients with dry eye. Invest. Ophthalmol. Visual Sci., 43:2609–2614, 2002.
20.
NiederkornJ.Y., SternM.E., PflugfelderS.C., et al.Desiccating stress induces T cell-mediated Sjogren's syndrome-like lacrimal keratoconjunctivitis. J. Immunol., 176:3950–3957, 2006.
21.
ElAnnan, J., ChauhanS.K., EcoiffierT., et al.Characterization of effector T cells in dry eye disease. Invest. Ophthalmol. Vis. Sci., 50:3802–3807, 2009.
22.
SchaumburgC.S., SiemaskoK.F., De PaivaC.S., et al.Ocular surface APCs are necessary for autoreactive T cell-mediated experimental autoimmune lacrimal keratoconjunctivitis. J. Immunol., 187:3653–3662, 2011.
23.
ChauhanS.K., El AnnanJ., EcoiffierT., et al.Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J. Immunol., 182:1247–1252, 2009.
24.
SakaguchiS.Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol., 22:531–562, 2004.
25.
PalmerM.T., and WeaverC.T.Autoimmunity: increasing suspects in the CD4+ T cell lineup. Nat. Immunol., 11:36–40, 2010.
26.
SiemaskoK.F., GaoJ., CalderV.L., et al.In vitro expanded CD4+CD25+Foxp3+ regulatory T cells maintain a normal phenotype and suppress immune-mediated ocular surface inflammation. Invest. Ophthalmol. Vis. Sci., 49:5434–5440, 2008.
27.
TangQ., HenriksenK.J., BiM., et al.In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med., 199:1455–1465, 2004.
28.
MastellerE.L., WarnerM.R., TangQ., et al.Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice. J. Immunol., 175:3053–3059, 2005.
29.
DursunD., WangM., MonroyD., et al.A mouse model of keratoconjunctivitis sicca. Invest. Ophthalmol. Vis. Sci., 43:632–638, 2002.
30.
De PaivaC.S., ChotikavanichS., PangelinanS.B., et al.IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol., 2:243–253, 2009.
31.
De PaivaC.S., VillarrealA.L., CorralesR.M., et al.Dry eye-induced conjunctival epithelial squamous metaplasia is modulated by interferon-gamma. Invest. Ophthalmol. Vis. Sci., 48:2553–2560, 2007.
32.
MassingaleM.L., LiX., VallabhajosyulaM., et al.Analysis of inflammatory cytokines in the tears of dry eye patients. Cornea., 28:1023–1027, 2009.
33.
KangM.H., KimM.K., LeeH.J., et al.Interleukin-17 in various ocular surface inflammatory diseases. J. Korean Med. Sci., 26:938–944, 2011.
34.
ManoussakisM.N., BoiuS., KorkolopoulouP., et al.Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjogren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development. Arthritis Rheum., 56:3977–3988, 2007.
35.
ChristodoulouM.I., KapsogeorgouE.K., and MoutsopoulosH.M.Characteristics of the minor salivary gland infiltrates in Sjogren's syndrome. J. Autoimmun., 34:400–407, 2010.
36.
ZhouD.L., ChenY.T., ChenF.L., et al.Critical involvement of macrophage infiltration in the development of Sjogren's syndrome-associated dry eye. Am. J. Pathol., 181:753–760, 2012.
37.
YouI.C., CourseyT.G., BianF., et al.Macrophage phenotype in the ocular surface of experimental murine dry eye disease. Arch. Immunol. Ther. Exp. (Warsz), 2015. [Epub ahead of print]; PMID:25772203.
38.
CrawfordS.E., StellmachV., Murphy-UllrichJ.E., et al.Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell., 93:1159–1170, 1998.
39.
Schultz-CherryS., ChenH., MosherD.F., et al.Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J. Biol. Chem., 270:7304–7310, 1995.
40.
ShevachE.M., DavidsonT.S., HuterE.N., DipaoloR.A., and AnderssonJ.Role of TGF-Beta in the induction of Foxp3 expression and T regulatory cell function. J. Clin. Immunol., 28:640–646, 2008.
41.
TurpieB., YoshimuraT., GulatiA., et al.Sjogren's syndrome-like ocular surface disease in thrombospondin-1 deficient mice. Am. J. Pathol., 175:1136–1147, 2009.
42.
Contreras-RuizL., RegenfussB., MirF.A., KearnsJ., and MasliS.Conjunctival inflammation in thrombospondin-1 deficient mouse model of Sjogren's syndrome. PLoS One., 8:e75937, 2013.
43.
RaphaelM., BellefqihS., PietteJ.C., et al.Conjunctival biopsy in Sjogren's syndrome: correlations between histological and immunohistochemical features. Histopathology., 13:191–202, 1988.
44.
WakamatsuT.H., SatoE.A., MatsumotoY., et al.Conjunctival in vivo confocal scanning laser microscopy in patients with Sjogren syndrome. Invest. Ophthalmol. Vis. Sci., 51:144–150, 2010.
45.
DoyenV., RubioM., BraunD., et al.Thrombospondin 1 is an autocrine negative regulator of human dendritic cell activation. J. Exp. Med., 198:1277–1283, 2003.
46.
SabanD.R., BockF., ChauhanS.K., MasliS., and DanaR.Thrombospondin-1 derived from APCs regulates their capacity for allosensitization. J. Immunol., 185:4691–4697, 2010.
47.
KodatiS., ChauhanS.K., ChenY., et al.CCR7 is critical for the induction and maintenance of Th17 immunity in dry eye disease. Invest. Ophthalmol. Vis. Sci., 55:5871–5877, 2014.
48.
MasliS., TurpieB., and StreileinJ.W.Thrombospondin orchestrates the tolerance-promoting properties of TGFbeta-treated antigen-presenting cells. Int. Immunol., 18:689–699, 2006.
49.
AwasthiA., MurugaiyanG., and KuchrooV.K.Interplay between effector Th17 and regulatory T cells. J. Clin. Immunol., 28:660–670, 2008.
50.
AviceM.N., RubioM., SergerieM., DelespesseG., and SarfatiM.CD47 ligation selectively inhibits the development of human naive T cells into Th1 effectors. J. Immunol., 165:4624–4631, 2000.
51.
GrimbertP., BouguermouhS., BabaN., et al.Thrombospondin/CD47 interaction: a pathway to generate regulatory T cells from human CD4+ CD25− T cells in response to inflammation. J. Immunol., 177:3534–3541, 2006.
52.
GandhiN.B., SuZ., ZhangX., et al.Dendritic cell-derived thrombospondin-1 is critical for the generation of the ocular surface Th17 response to desiccating stress. J. Leukoc. Biol., 94:1293–1301, 2013.
53.
CursiefenC.Immune privilege and angiogenic privilege of the cornea. Chem. Immunol. Allergy., 92:50–57, 2007.
54.
GoyalS., ChauhanS.K., El AnnanJ., et al.Evidence of corneal lymphangiogenesis in dry eye disease: a potential link to adaptive immunity?. Arch. Ophthalmol., 128:819–824, 2010.
55.
CursiefenC., ChenL., BorgesL.P., et al.VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J. Clin. Invest., 113:1040–1050, 2004.
56.
MaruyamaK., IiM., CursiefenC., et al.Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J. Clin. Invest., 115:2363–2372, 2005.
57.
MimuraT., AmanoS., UsuiT., et al.Expression of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in corneal lymphangiogenesis. Exp. Eye Res., 72:71–78, 2001.
58.
ChauhanS.K., JinY., GoyalS., et al.A novel pro-lymphangiogenic function for Th17/IL-17. Blood., 118:4630–4634, 2011.
59.
StreileinJ.W.Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat. Rev. Immunol., 3:879–889, 2003.
60.
CursiefenC., MasliS., NgT.F., et al.Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest. Ophthalmol. Vis. Sci., 45:1117–1124, 2004.
61.
BagavandossP., and WilksJ.W.Specific inhibition of endothelial cell proliferation by thrombospondin. Biochem. Biophys. Res. Commun., 170:867–872, 1990.
62.
KaurS., Martin-MansoG., PendrakM.L., et al.Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47. J. Biol. Chem., 285:38923–38932, 2010.
63.
DawsonD.W., PearceS.F., ZhongR., et al.CD36 mediates the in vitro inhibitory effects of thrombospondin-1 on endothelial cells. J. Cell Biol., 138:707–717, 1997.
64.
JimenezB., VolpertO.V., CrawfordS.E., et al.Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med., 6:41–48, 2000.
65.
CursiefenC., MaruyamaK., BockF., et al.Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes. J. Exp. Med., 208:1083–1092, 2011.
66.
Contreras-RuizL., RyanD.S., SiaR.K., et al.Polymorphism in THBS1 gene is associated with post-refractive surgery chronic ocular surface inflammation. Ophthalmology., 121:1389–1397, 2014.
67.
StreileinJ.W., YamadaJ., DanaM.R., and KsanderB.R.Anterior chamber-associated immune deviation, ocular immune privilege, and orthotopic corneal allografts. Transplant. Proc., 31:1472–1475, 1999.
68.
KuchleM., CursiefenC., NguyenN.X., et al.Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study. Graefes Arch. Clin. Exp. Ophthalmol., 240:580–584, 2002.
69.
HosD., and CursiefenC.Lymphatic vessels in the development of tissue and organ rejection. Adv. Anat. Embryol. Cell Biol., 214:119–141, 2014.
70.
DanaM.R., and StreileinJ.W.Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest. Ophthalmol. Vis. Sci., 37:2485–2494, 1996.
71.
KaplanH.J., StreileinJ.W., and StevensT.R.Transplantation immunology of the anterior chamber of the eye. II. Immune response to allogeneic cells. J. Immunol., 115:805–810, 1975.
72.
CursiefenC., ChenL., DanaM.R., and StreileinJ.W.Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology. Cornea., 22:273–281, 2003.
73.
NiederkornJ.Y.The immune privilege of corneal allografts. Transplantation., 67:1503–1508, 1999.
74.
MaguireM.G., StarkW.J., GottschJ.D., et al.Risk factors for corneal graft failure and rejection in the collaborative corneal transplantation studies. Collaborative Corneal Transplantation Studies Research Group. Ophthalmology., 101:1536–1547, 1994.
75.
SanoY., KsanderB.R., and StreileinJ.W.Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction. Invest. Ophthalmol. Vis. Sci., 36:2176–2185, 1995.
76.
DanaM.R., SchaumbergD.A., KowalV.O., et al.Corneal neovascularization after penetrating keratoplasty. Cornea., 14:604–609, 1995.
77.
BachmannB., TaylorR.S., and CursiefenC.Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology., 117:1300–1305 e1307, 2010.
78.
JagerM.J.Corneal Langerhans cells and ocular immunology. Reg. Immunol., 4:186–195, 1992.
79.
StreileinJ.W., ToewsG.B., and BergstresserP.R.Corneal allografts fail to express Ia antigens. Nature., 282:326–327, 1979.
80.
PeelerJ.S., and NiederkornJ.Y.Antigen presentation by Langerhans cells in vivo: donor-derived Ia+Langerhans cells are required for induction of delayed-type hypersensitivity but not for cytotoxic T lymphocyte responses to alloantigens. J. Immunol., 136:4362–4371, 1986.
81.
ShoskesD.A., and WoodK.J.Indirect presentation of MHC antigens in transplantation. Immunol. Today., 15:32–38, 1994.
82.
BenichouG., TakizawaP.A., OlsonC.A., McmillanM., and SercarzE.E.Donor major histocompatibility complex (Mhc) peptides are presented by recipient Mhc molecules during graft-rejection. J. Exp. Med., 175:305–308, 1992.
83.
YamagamiS., and DanaM.R.The critical role of lymph nodes in corneal alloimmunization and graft rejection. Invest. Ophthalmol. Vis. Sci., 42:1293–1298, 2001.
84.
YamagamiS., DanaM.R., and TsuruT.Draining lymph nodes play an essential role in alloimmunity generated in response to high-risk corneal transplantation. Cornea., 21:405–409, 2002.
85.
LiuY., HamrahP., ZhangQ., TaylorAW., and DanaM.R.Draining lymph nodes of corneal transplant hosts exhibit evidence for donor major histocompatibility complex (MHC) class II-positive dendritic cells derived from MHC class II-negative grafts. J. Exp. Med., 195:259–268, 2002.
86.
HuqS., LiuY., BenichouG., and DanaM.R.Relevance of the direct pathway of sensitization in corneal transplantation is dictated by the graft bed microenvironment. J. Immunol., 173:4464–4469, 2004.
87.
CursiefenC., Schlotzer-SchrehardtU., KuchleM., et al.Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. Invest. Ophthalmol. Vis. Sci., 43:2127–2135, 2002.
88.
CursiefenC., CaoJ., ChenL., et al.Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest. Ophthalmol. Vis. Sci., 45:2666–2673, 2004.
89.
BachmannB.O., BockF., WiegandS.J., et al.Promotion of graft survival by vascular endothelial growth factor a neutralization after high-risk corneal transplantation. Arch. Ophthalmol., 126:71–77, 2008.
90.
BachmannB.O., Luetjen-DrecollE., BockF., et al.Transient postoperative vascular endothelial growth factor (VEGF)-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation. Br. J. Ophthalmol., 93:1075–1080, 2009.
91.
BockF., OnderkaJ., DietrichT., et al.Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation. Graefes Arch. Clin. Exp. Ophthalmol., 246:115–119, 2008.
92.
DietrichT., OnderkaJ., BockF., et al.Inhibition of inflammatory lymphangiogenesis by integrin alpha5 blockade. Am. J. Pathol., 171:361–372, 2007.
93.
DietrichT., BockF., YuenD., et al.Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J. Immunol., 184:535–539, 2010.
WilbanksG.A., and StreileinJ.W.Studies on the induction of anterior chamber-associated immune deviation (ACAID). 1. Evidence that an antigen-specific, ACAID-inducing, cell-associated signal exists in the peripheral blood. J. Immunol., 146:2610–2617, 1991.
96.
WilbanksG.A., MammolentiM., and StreileinJ.W.Studies on the induction of anterior chamber-associated immune deviation (ACAID). II. Eye-derived cells participate in generating blood-borne signals that induce ACAID. J. Immunol., 146:3018–3024, 1991.
97.
WilbanksG.A., and StreileinJ.W.Macrophages capable of inducing anterior chamber associated immune deviation demonstrate spleen-seeking migratory properties. Reg. Immunol., 4:130–137, 1992.
98.
SonodaK.H., ExleyM., SnapperS., BalkS.P., and Stein-StreileinJ.CD1-reactive natural killer T cells are required for development of systemic tolerance through an immune-privileged site. J. Exp. Med., 190:1215–1226, 1999.
99.
FaunceD.E., SonodaK.H., and Stein-StreileinJ.MIP-2 recruits NKT cells to the spleen during tolerance induction. J. Immunol., 166:313–321, 2001.
100.
MasliS., TurpieB., HeckerK.H., and StreileinJ.W.Expression of thrombospondin in TGFbeta-treated APCs and its relevance to their immune deviation-promoting properties. J. Immunol., 168:2264–2273, 2002.
101.
TakeuchiM., AlardP., and StreileinJ.W.TGF-beta promotes immune deviation by altering accessory signals of antigen-presenting cells. J. Immunol., 160:1589–1597, 1998.
102.
WilbanksG.A., and StreileinJ.W.Characterization of suppressor cells in anterior chamber-associated immune deviation (ACAID) induced by soluble antigen. Evidence of two functionally and phenotypically distinct T-suppressor cell populations. Immunology., 71:383–389, 1990.
103.
KosiewiczM.M., and StreileinJ.W.Intraocular injection of class II-restricted peptide induces an unexpected population of CD8 regulatory cells. J. Immunol., 157:1905–1912, 1996.
104.
Stein-StreileinJ., and StreileinJ.W.Anterior chamber associated immune deviation (ACAID): regulation, biological relevance, and implications for therapy. Int. Rev. Immunol., 21:123–152, 2002.
105.
KezukaT., and StreileinJ.W.Analysis of in vivo regulatory properties of T cells activated in vitro by TGFbeta2-treated antigen presenting cells. Invest. Ophthalmol. Vis. Sci., 41:1410–1421, 2000.
106.
TakeuchiM., KosiewiczM.M., AlardP., and StreileinJ.W.On the mechanisms by which transforming growth factor-beta 2 alters antigen-presenting abilities of macrophages on T cell activation. Eur. J. Immunol., 27:1648–1656, 1997.
107.
VallejoA.N., MuggeL.O., KlimiukP.A., WeyandC.M., and GoronzyJ.J.Central role of thrombospondin-1 in the activation and clonal expansion of inflammatory T cells. J. Immunol., 164:2947–2954, 2000.
108.
GaoA.G., LindbergF.P., FinnM.B., et al.Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin. J. Biol. Chem., 271:21–24, 1996.
109.
ArmantM., AviceM.N., HermannP., et al.CD47 ligation selectively downregulates human interleukin 12 production. J. Exp. Med., 190:1175–1182, 1999.
110.
WintonH.L., BidwellJ.L., and ArmitageW.J.Thrombospondin-1 polymorphisms influence risk of corneal allograft rejection. Invest. Ophthalmol. Vis. Sci., 55:2115–2120, 2014.
